Heart transplantation: Organisational aspects and current trends in immunosuppression - A view from Spain

Heart

Volumn 98, Issue 11, 2012, Pages 878-889

  Alonso Pulpón, Luis ^a   Segovia, Javier ^a   Goḿez Bueno, Manuel ^a   Garciá Pavía, Pablo ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALOPECIA; ANEMIA; ASEPTIC MENINGITIS; BACTERIAL INFECTION; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CARDIAC GRAFT REJECTION; CATARACT; CHILL; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CUSHINGOID SYNDROME; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ENCEPHALITIS; FEVER; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GRAFT DYSFUNCTION; HEADACHE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMATOLOGIC DISEASE; HEPATITIS; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; INFECTION; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE CHEMOTHERAPY; MELANOMA SKIN CANCER; MENTAL INSTABILITY; MONOTHERAPY; MOUTH ULCER; MUCOSA INFLAMMATION; MYOPATHY; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ORGAN DONOR; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; SPAIN; SPEECH DISORDER; STEROID THERAPY; STOMACH ULCER; STOMATITIS; THROMBOCYTOPENIA; TREMOR; TREND STUDY; VOMITING; WHEEZING; WOUND HEALING IMPAIRMENT;

AGED; EVIDENCE-BASED MEDICINE; FEMALE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; PATIENT SELECTION; QUALITY OF LIFE; SPAIN; SURVIVAL RATE; TISSUE AND ORGAN PROCUREMENT;

EID: 84862060010     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300479     Document Type: Review

References (17)

1. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010;122:173-83. An updated review on indications of heart transplant in the era of mechanical circulatory support devices.
2. Stehlik J, Edwards LB, Kucheryavaya AY, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report - 2010. J Heart Lung Transplant 2010;29:1089-103. Based upon the data of a voluntary registry including more than 60% of heart transplants performed worldwide, this article gives an excellent overview of the current status of the technique. It also contains data on trends in immunosuppression, risk factors for post- transplant mortality, impact of the main complications, and functional status of heart recipients.
3. International Figures on Organ Donation and Transplantation - 2009. Newsletter Transplant, 2010:15. http://www.ont.es/publicaciones/Documents/ Newsletter2010.pdf
4. Almenar L, Segovia J, Crespo-Leiro MG, et al Spanish Heart Transplantation Registry. 21st Official Report of the Spanish Society of Cardiology Working Group on Heart Failure and Heart Transplantation (1984-2009). Rev Esp Cardiol 2010;63:1317-28. A reliable source of information about 'real life' transplantation, since the Spanish registry includes each and every heart transplant performed in this country since 1984, totalling over 6000 cases. It Includes information on waiting lists, overall results of the procedure, and analysis of the causes of mortality.
5. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 2004;110:3734-40. First of a series of four articles in consecutive issues of the same journal (see refs w3-w5) providing a comprehensive, broad-scope review of classic immunosuppressive therapy in heart transplantation.
6. Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol 2008;52:587-98.
7. Costanzo MR. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29:914-56. Conceived and written in the style of Clinical Practice Guidelines so successful in other areas of cardiology, these guidelines - necessarily lacking in evidence on which to be based - are a list of experts' opinions in different areas of the care of cardiac transplant recipients.
8. Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant 2011;30:115-23. This systematic registry of all the implants of mechanical circulatory assist devices performed in the USA since 2006 is the most updated source of information on the achievements and limitations of these devices. It includes a specific analysis of the results of devices implanted as destination therapy, the only real alternative to heart transplantation.
9. Matesanz R, Domínguez-Gil B. Strategies to optimise deceased organ donation. Transplant Rev 2007;21:177-88. (Pubitemid 47506507)
10. Fabre J, Murphy P, Matesanz R. Presumed consent: a distraction in the quest for increasing rates of organ donation. BMJ 2010;341:c4973.
11. Crespo-Leiro MG, Alonso-Pulpón L, Vázquez de Prada JA, et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant 2008;8:1031-9. Exhaustive description of all malignancies diagnosed in a large consecutive series of heart transplant recipients from the Spanish Registry of Heart Transplantation. (Pubitemid 351537770)
12. Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006;81:1542-8. (Pubitemid 43890891)
13. Patel J, Kobashigawa JA. Minimization of immunosuppression. Transplant Immunol 2008;20:48-54. Insightful review of the different strategies to minimise immunosuppression in heart transplantation over the last 25 years.
14. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 2010;10:382-8.
15. Baran DA, Zucker MJ, Arroyo LH, et al. Prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail 2011;4:129-37.
16. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010;362:1890-900.
17. Israeli M, Ben-Gal T, Yaari V, et al. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests. Transplantation 2010;89:968-76.